20 completed, 5 unknown, 4 terminated, 1 no longer available. 11 Phase 2, 6 Phase 3, 4 Phase 1, 3 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 6, Unknown 4, Terminated 1 |
| Phase 3 | 6 | Completed 5, Terminated 1 |
| Phase 1 | 4 | Completed 4 |
| Phase 4 | 3 | Completed 2, Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow Ad26COVS1: new trials by email Literature Review of Ad26COVS1 trials Research Report on Ad26COVS1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults. Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer) - COVID-19 | Phase 2 | Unknown | The Aurum Institute NPC | 694 | 2022-07-25 | 2024-07-15 |
| Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study ChAdOx1 nCOV-19 vaccine (Vaxzeria), BNT162b2 (Pfizer), Ad26.COV2.S (Janssen) - COVID-19 | Completed | AstraZeneca | 188814085 | 2022-07-22 | 2024-11-21 | |
| Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine Ad26.COV2.S - COVID-19, Vaccine Reaction | Phase 2 | Unknown | ANRS, Emerging Infectious Diseases | 200 | 2022-06-02 | 2024-03-27 |
| Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell), Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein),, Placebo - Normal saline (0.9% sodium chloride solution) - Covid19 | Phase 2 | Unknown | International Vaccine Institute | 360 | 2021-12-29 | 2023-04-19 |
| Transverse Myelitis Related to SARS-CoV-2 Vaccines SARS-CoV-2 vaccines - Vaccine Adverse Reaction | Completed | University Hospital, Caen | 580 | 2021-12-10 | 2022-01-05 | |
| Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study. Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S - SARS CoV 2 Infection | Phase 3 | Completed | Wits Health Consortium (Pty) Ltd | 500000 | 2021-11-10 | 2026-09-01 |
| A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine, CoronaVac COVID-19 vaccine, ChAdOx1 nCoV-19 Covid-19 Vaccine - Covid19 | Completed | Hospital Moinhos de Vento | 4574 | 2021-11-03 | 2023-11-07 | |
| A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults Ad26.COV2.S, Placebo, Influenza Vaccine - COVID-19 Prevention | Phase 3 | Completed | Janssen Vaccines & Prevention B.V. | 861 | 2021-11-02 | 2025-05-25 |
| RECOVAC Repeated Vaccination Study mRNA-1273, Ad26.COV2.S vaccine - Covid19, Kidney Diseases | Phase 4 | Completed | University Medical Center Groningen | 336 | 2021-10-21 | 2022-03-29 |
| A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive Ad26.COV2.S - Coronavirus Disease-2019 (COVID-19) Prevention | Phase 2 | Completed | Janssen Vaccines & Prevention B.V. | 304 | 2021-09-27 | 2025-02-04 |
| Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen COVID-19 Vaccine Janssen (Ad26.COV2-S) - Healthy Volunteers | Phase 4 | Terminated | Centre Hospitalier Universitaire de Saint Etienne | 27 | 2021-09-20 | 2025-02-10 |
| COVID-19 3rd Dose Vaccine in Transplant Patients BNT162b2 vaccine, JNJ-78436735 Vaccine - Covid19 | Phase 3 | Terminated | Giselle Guerra | 58 | 2021-09-14 | 2024-06-04 |
| A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) Ad26.COV2.S - COVID-19 Prevention | Phase 2 | Completed | Janssen Vaccines & Prevention B.V. | 51 | 2021-08-27 | 2025-05-25 |
| COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders Moderna mRNA-1273, BNT162b2, Ad26.COV2.S - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 258 | 2021-08-13 | 2026-06-10 |
| A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2 Ad26.COV2.S - Coronavirus Disease | Phase 2 | Completed | Janssen Vaccines & Prevention B.V. | 1541 | 2021-08-06 | 2025-02-04 |
| A Phase IV Vaccine Study Under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2 (COVID-19) Vaccines. Johnson & Johnson - SARS CoV 2 Infection | Phase 4 | Completed | Jens D Lundgren, MD | 25 | 2021-07-05 | 2024-04-11 |
| Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC) COVID-19 Vaccination - Cancer | Terminated | Indiana University | 2206 | 2021-06-30 | 2023-05-19 | |
| A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults Ad26.COV2.S - COVID-19 Prevention | Phase 3 | Completed | Janssen Vaccines & Prevention B.V. | 1609 | 2021-06-18 | 2025-02-04 |
| Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant Recipients Ad26COVS1, ChAdOx1 SARS2 Vaccine, BNT162B2 - COVID-19 | Phase 2 | Unknown | Medical University of Vienna | 200 | 2021-06-15 | 2022-04-20 |
| Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines Ad26.COV2.S, BNT162b2, mRNA-1273 - COVID-19 | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 867 | 2021-05-28 | 2025-04-20 |
Showing 20 of 31. Sign in to see all of them.
COVID-19 (18) · Arthritis, Juvenile (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Dermatitis, Atopic (1) · Dermatomyositis (1) · Drug-Related Side Effects and Adverse Reactions (1) · Kidney Diseases (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Long Term Adverse Effects (1) · Lupus Erythematosus, Systemic (1) · Multiple Sclerosis (1) · Neoplasms (1) · Pemphigus (1) · Scleroderma, Systemic (1)
Janssen Vaccines & Prevention B.V. (10) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · ANRS, Emerging Infectious Diseases (1) · AstraZeneca (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Giselle Guerra (1) · Hospital Moinhos de Vento (1) · Indiana University (1) · International Vaccine Institute (1) · Janssen Pharmaceutical K.K. (1) · Janssen Research & Development, LLC (1) · Jens D Lundgren, MD (1) · Masaryk University (1) · Massachusetts General Hospital (1) · Mebo Research, Inc. (1)
United States (15) · Brazil (7) · South Africa (7) · Germany (4) · Belgium (3) · France (3) · Mexico (3) · Netherlands (3) · Poland (3) · United Kingdom (3) · Argentina (2) · Colombia (2) · Spain (2) · Austria (1) · Canada (1)
Amit Bar-Or, MD, FRCP (1) · Dinesh Khanna, MBBS, MSc (1) · Eric Simpson, MD, MCR (1) · Florian Marks, PhD (1) · Giselle Guerra, MD (1) · Glenda Gray, MBChB (1) · Ilesh Jani, PhD (1) · Irene Gabashvili, PhD (1) · Jan-Stephan F Sanders, MD PhD (1) · Jens Lundgren, Professor (1) · Judith A. James, MD, PhD (1)
PMID 35667914, PMID 33083026, PMID 33440088, PMID 33524316, PMID 33704352, PMID 33882225, PMID 34360156, PMID 34824596, PMID 35073571, PMID 35081293, PMID 35139271, PMID 35798000, PMID 36113538, PMID 36309347, PMID 36354032, PMID 36357712, PMID 36732164, PMID 37091963, PMID 37385888, PMID 37433788, PMID 37992183, PMID 38278629, PMID 38467646, PMID 38705804, PMID 38902860, PMID 38918103, PMID 39121698, PMID 39225478, PMID 39272117, PMID 39532861, PMID 39798807, PMID 39866854, PMID 39868766, PMID 40068393, PMID 40298376, PMID 40694514, PMID 40808283, PMID 41289027, PMID 41690324
5UM1AI148684-02 (1)